Abvc Biopharma (ABVC) Change in Account Payables (2010 - 2024)
Abvc Biopharma's (ABVC) quarterly Change in Account Payables came in at $92972.0 in Q3 2024, up 118.65% YoY from $42521.1 in Q4 2023, and up 282.19% on a QoQ basis from $24326.0 in Q2 2024.
Abvc Biopharma (ABVC) Change in Account Payables (2010 - 2024) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Change in Account Payables data on file, last reported at $92972.0 in Q3 2024.
- Quarterly Change in Account Payables rose 118.65% year-over-year to $92972.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $214975.0 (up 657.75% YoY) and the FY2023 annual result came in at -$186860.0, down 177.07% from the prior year.
- Change in Account Payables climbed to $92972.0 in Q3 2024, from $24326.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $849033.0 in Q4 2020 to a low of -$566059.0 in Q3 2020.
- A 5-year average of $28710.2 and a median of $2586.0 in 2021 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 3012.38% — and 2023, when it slumped 2129.8%.
- Tracing ABVC's Change in Account Payables over 5 years: stood at $849033.0 in 2020, then sank by 101.94% to -$16497.0 in 2021, then jumped by 1215.76% to $184067.0 in 2022, then slumped by 116.93% to -$31163.0 in 2023, then surged by 398.34% to $92972.0 in 2024.
- The last three Change in Account Payables figures came in at $92972.0 (Q3 2024), $24326.0 (Q2 2024), and $128840.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 92,972.00 |
| Sep 30, 2024 | 92,972.00 |
| Jun 30, 2024 | 24,326.00 |
| Jun 30, 2024 | 24,326.00 |
| Mar 31, 2024 | 128,840.00 |
| Mar 31, 2024 | 128,840.00 |
| Dec 31, 2023 | -31,163.00 |
| Dec 31, 2023 | -31,163.00 |
| Sep 30, 2023 | -498,538.00 |
| Sep 30, 2023 | -498,538.00 |
| Jun 30, 2023 | -32,613.00 |
| Jun 30, 2023 | -32,613.00 |
| Mar 31, 2023 | 375,454.00 |
| Mar 31, 2023 | 375,454.00 |
| Dec 31, 2022 | 184,067.00 |
| Dec 31, 2022 | 184,067.00 |
| Sep 30, 2022 | -22,358.00 |
| Sep 30, 2022 | -22,358.00 |
| Jun 30, 2022 | 23,461.00 |
| Jun 30, 2022 | 23,461.00 |